Compounded bioidentical hormone replacement therapy (cBHRT) is in peril. Help support a sign-on letter in Congress telling the FDA NOT to limit access to these treatments. Action Alert! The letter, circulated by Reps. Jennifer Wexton (D-VA) and Michael Burgess (R-TX), draws attention to many of the issues with the FDA’s process we’ve discussed in our Pulse newsletter in the past, urging the FDA to enact policies that allow patients to continue using cBHRT. Read more.